SCHEMBL21024070

SCHEMBL21024070

CNC(=O)c1c[nH]c2c(C)nc(C(C)C)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CREBBP Q92793 4/20 0.40
▸ AR P10275 2/20 0.38
▸ CYP17A1 P05093 2/20 0.36
▸ TLR8 Q9NR97 2/20 0.36
▸ TLR7 Q9NYK1 2/20 0.36
▸ TRIM24 O15164 1/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ EP300 Q09472 1/20 0.35
▸ BRD3 Q15059 1/20 0.35
▸ BRD9 Q9H8M2 1/20 0.35
▸ BRD7 Q9NPI1 1/20 0.35
▸ PDK2 Q15119 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ NR1I2 O75469 1/20 0.34
▸ AHR P35869 1/20 0.34
▸ NR4A2 P43354 1/20 0.33
▸ SYK P43405 1/20 0.33
▸ CCNC P24863 1/20 0.33
▸ CDK8 P49336 1/20 0.33
▸ BRPF1 P55201 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22822516 0.78 CREBBP (0.40) CREBBPARCYP17A1TRIM24BRD4
SCHEMBL19657571 0.75 CREBBP (0.41) CREBBPARTRIM24BRD4EP300
SCHEMBL21024066 0.73 CREBBP (0.43) CREBBPARCYP17A1TRIM24BRD4
SCHEMBL30993004 0.71 CREBBP (0.45) CREBBPARTRIM24BRD4EP300
SCHEMBL21024069 0.69 CREBBP (0.41) CREBBPCYP17A1TRIM24BRD4EP300
SCHEMBL30993163 0.69 CREBBP (0.39) CREBBPARCYP17A1EP300PDK2
SCHEMBL19657570 0.66 AR (0.41) CREBBPARCYP17A1PDK2CYP3A4
SCHEMBL30993273 0.66 AR (0.34) CREBBPARCYP17A1EP300NR1I2
SCHEMBL30993555 0.66 CREBBP (0.42) CREBBPARBRD4NR4A2BRPF1
SCHEMBL22822512 0.65 CREBBP (0.35) CREBBPARCYP17A1TRIM24BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10696655-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2020-06-30 — — US disclosed
US-20190152949-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2019-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152949-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC11 CREBBP 6/4885AR 1194/4885CYP17A1 2878/4885
US-10696655-B2 Therapeutic compounds and uses thereof EP300, HDAC1, HDAC11 CREBBP 6/4885AR 1194/4885CYP17A1 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback